How many insider trades does FilingIQ track for IMMX?

FilingIQ tracks 79 Form 4 insider transactions for IMMX (Immix Biopharma, Inc.), covering filings from Dec 17, 2021 onwards. 16 of those were filed in the last 90 days.

Are IMMX insiders net buyers or net sellers?

Across the full Form 4 history for IMMX, 42 transactions (53%) were open-market purchases and 2 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IMMX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IMMX in?

Immix Biopharma, Inc. (IMMX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $431.66M.

IMMX insider trading

NasdaqCM Healthcare

Immix Biopharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

53% / 3%

Market cap

$431.66M

About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Company website: www.immixbio.com

IMMX insider activity at a glance

FilingIQ has scored 79 insider transactions for IMMX since Dec 17, 2021. The most recent filing in our index is dated May 22, 2026.

Across the full history, 42 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IMMX insider trades is 56.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IMMX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,265

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 195

Guardant Health, Inc.

ADPT 184

Adaptive Biotechnologies Corp

BMY 182

BRISTOL MYERS SQUIBB CO

VTRS 165

Viatris Inc

ALNY 153

ALNYLAM PHARMACEUTICALS, INC.

Frequently asked

How many insider trades does FilingIQ track for IMMX?: FilingIQ tracks 79 Form 4 insider transactions for IMMX (Immix Biopharma, Inc.), covering filings from Dec 17, 2021 onwards. 16 of those were filed in the last 90 days.
Are IMMX insiders net buyers or net sellers?: Across the full Form 4 history for IMMX, 42 transactions (53%) were open-market purchases and 2 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IMMX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IMMX in?: Immix Biopharma, Inc. (IMMX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $431.66M.

Methodology & sources

Every IMMX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.